GoodRx won't be participating with TrumpRx: report

2025-11-07 04:17

GoodRx (GDRX), the company that provides a platform for consumers to get cheaper prescriptions drugs both online and at pharmacies, will not partner with TrumpRx, a federal government website that will connect consumers with lower-priced medications.
CBS News Senior White Reporter Jennifer Jacobs said that a government official told her TrumpRx is designed to transfer patients to a particular drugmaker's website to make a discounted drug purchase. TrumpRx is expected to begin operations in January 2026.
"The companies will decide how to fulfill those orders – via their own in-house logistics or by partnering with a 3rd-party platform," Jacobs wrote in an X post.
GoodRx shares are down ~5% following the post.
A request for comment from GoodRx has yet to be returned to Seeking Alpha.
Pfizer (PFE), AstraZeneca (AZN), EMD Serono (OTCPK:MKGAF), and most recently, Novo Nordisk (NVO), have agreed to participate in TrumpRx, part of the president's "Most Favored Nation" drug-pricing policy. In October, Amgen (AMGN) began offering its PCSK9 inhibitor cholesterol therapy Repatha (evolocumab) on its direct-to-consumer platform AmgenNow for $239 a month, a 60% discount of its list price.

More on GoodRx Holdings